Madrigal Pharmaceuticals CCO Makes a Significant Stock Sale!

New insider activity at Madrigal Pharmaceuticals ( (MDGL) ) has taken place on November 21, 2025.

Carole Huntsman, the Chief Commercial Officer of Madrigal Pharmaceuticals, has recently sold 894 shares of the company’s stock, amounting to a total transaction value of $492,567.

Recent Updates on MDGL stock

Madrigal Pharmaceuticals reported a strong third quarter, driven by the successful launch of Rezdiffra, which saw a 35% increase in net sales to $287 million. The company’s financial health remains robust with $1.1 billion in cash and marketable securities, despite increased operating expenses due to R&D investments and SG&A costs. A significant development was the U.S. patent extension for Rezdiffra, securing its market position until 2045, and its launch in Germany following European approval. The company faces challenges with payer contracting and competitive pressures in the MASH market. Analysts have upgraded the stock, citing the outperformance of Rezdiffra and clarity on future growth prospects, with expectations of profitability by 2026.

Spark’s Take on MDGL Stock

According to Spark, TipRanks’ AI Analyst, MDGL is a Neutral.

Madrigal Pharmaceuticals presents a mixed investment case. Strong revenue growth and a successful product launch boost its appeal, but profitability remains a challenge due to high operational costs. The stable balance sheet offers some reassurance, though ongoing cash burn and external financing reliance are risks. Technical indicators suggest a neutral stance with potential for growth, while the valuation reflects the high-risk nature typical of biotech firms.

To see Spark’s full report on MDGL stock, click here.

More about Madrigal Pharmaceuticals

YTD Price Performance: 72.77%

Average Trading Volume: 347,113

Technical Sentiment Signal: Buy

Current Market Cap: $12.62B